NEW YORK (GenomeWeb) – Invitae has commenced an underwritten public offering of $40 million worth of shares of its common stock, the company said yesterday.

All shares of common stock are offered by Invitae before deducting underwriting discounts, commissions or other expenses. JP Morgan Securities is the book-running manager for the offering.

Invitae said it will offer the underwriter a 30-day option to buy an as much as $6 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Feb
22
Sponsored by
SeraCare

This webinar will walk through key considerations and helpful guidelines to accelerate next-generation sequencing (NGS)-based clinical genomics assay validation for less money and greater confidence in results.

Feb
27

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep. 

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.